Señales en vivo de VYNE | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	15 849.00
Volumen promedio	106 139
Capitalización de mercado	35.25M
EPS	$0 ( 2024-03-14 )
Próxima fecha de ganancias	( $-0.240 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.920
ATR14	$0.0240 (0.97%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Zeronda Tyler	Sell	94	Common Stock
2024-04-01	Stuart Iain	Sell	157	Common Stock
2024-04-01	Harsch Mutya	Sell	161	Common Stock
2024-04-01	Domzalski David	Sell	1 004	Common Stock
2024-01-01	Zeronda Tyler	Buy	62 500	Common Stock

INSIDER POWER
-56.80
Last 99 transactions
Buy: 3 356 313 \| Sell: 7 897 303

Volumen Correlación

Largo: 0.36 (neutral)

Corto: -0.34 (neutral)

Signal:(51.533) Neutral

VYNE Therapeutics Inc. Correlación

10 Correlaciones Más Positivas
ALBO	0.962
CMPI	0.962
OCSL	0.934
PALT	0.913
IRMD	0.911
PLRX	0.91
MLAC	0.905
ANDE	0.905
NATI	0.903
DRNA	0.902

10 Correlaciones Más Negativas
CFV	-0.951
AKAM	-0.888
BNIXU	-0.882
GMII	-0.88
TUEM	-0.874
EAR	-0.85
SHLD	-0.845
TRMK	-0.84
DTSS	-0.838
VIVE	-0.837

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

VYNE Therapeutics Inc. Correlación - Moneda/Commodity

0.49
( neutral )

0.50
( neutral )

0.00
( neutral )

0.37
( neutral )

-0.29
( neutral )

0.17
( neutral )

VYNE Therapeutics Inc. Finanzas

Annual	2023
Ingresos:	$424 000
Beneficio Bruto:	$424 000 (100.00 %)
EPS:	$-2.77

FY	2023
Ingresos:	$424 000
Beneficio Bruto:	$424 000 (100.00 %)
EPS:	$-2.77

FY	2022
Ingresos:	$477 000
Beneficio Bruto:	$477 000 (100.00 %)
EPS:	$-10.65

FY	2021
Ingresos:	$14.76M
Beneficio Bruto:	$11.41M (77.31 %)
EPS:	$-1.420

Financial Reports:

No articles found.

VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.